The Best Treatment for Meth Is $225 a Month in Gift Cards. The Federal Limit Is $75.

There are no FDA-approved medications for methamphetamine use disorder. There are none for cocaine use disorder. Almost 40 years of pharmaceutical research has not produced a pill or injection that reliably breaks the grip of stimulant addiction. In 2026, more than half of all U.S. drug overdose deaths involve stimulants — methamphetamine, cocaine, or prescription stimulants, often in combination with fentanyl. The people dying do not have a medication waiting for them.

What they do have is contingency management. And the federal government will fund it up to $75 per person.

Contingency management (CM) is a behavioral treatment built on a simple premise: people are more likely to stay off drugs when staying off drugs is immediately rewarded. Participants submit regular drug tests, and negative results are met with tangible incentives — typically gift cards or vouchers in escalating amounts for consecutive clean tests. The evidence for CM in stimulant use disorder is as solid as anything in addiction medicine. It is described by SAMHSA as the gold standard for stimulant SUD treatment. The Johns Hopkins opioid principles resource on CM notes it has the strongest evidence base of any behavioral treatment for stimulants. This is not a dispute in the literature.

The evidence-based dose is $200–300 per month in incentives for three to six months of treatment. That’s what the controlled trials used. That’s what produces outcomes.

Federal funding programs for CM are capped at $75 per participant — total, not per month. Not per quarter. The cap, embedded in federal grants dating back years, was set at a level that makes real CM impossible to deliver. According to the APA’s April 2026 analysis, that $75 limit is the single most significant structural barrier to CM reaching the people who need it. Programs that receive federal funds cannot legally exceed it. Programs that want to run CM at the evidence-based level have to find private, state, or philanthropic money to close the gap — or cap their incentives and deliver a diluted version of the treatment.

Think about what this means for someone seeking treatment for methamphetamine use disorder. The community mental health center they walk into might be running a “contingency management program” that gives $5 gift cards for negative tests. The version of CM proven to work in trials gave $75 in week one, escalating over twelve weeks to substantially more — building momentum, rewarding accumulation of clean time, making abstinence financially meaningful during the period when cravings are at their highest. The version funded by federal grants at $75 total doesn’t do that. It’s CM in name only.

SAMHSA released updated guidelines in 2026 intended to expand access to CM, and there has been real legislative momentum — the TREAT Act and related bills have proposed lifting or eliminating the federal cap. That momentum has not yet translated into an actual cap increase or elimination. The guidelines are real. The funding constraint is also real. Right now, a program following SAMHSA’s updated guidance still hits the $75 wall the moment federal dollars are involved.

The psychology at work in CM is not complicated, and it is also not optional. Stimulant use disorders are characterized by dysregulation of the brain’s reward circuitry — dopamine pathways that have been hijacked by drug use now respond weakly to ordinary rewards, making the early weeks and months of abstinence a period of anhedonia and craving in which the abstract benefit of sobriety can’t compete with the immediate pull of the drug. CM works by inserting concrete, immediate, tangible rewards into that moment. It doesn’t fix the neurobiology, but it creates a behavioral scaffold that can support abstinence long enough for the brain to begin recovering.

It doesn’t fix the neurobiology, but it creates a behavioral scaffold that can support abstinence long enough for the brain to begin recovering.

The cap means most people who walk into a federally-funded program for meth treatment won’t get the scaffold they need. That isn’t a policy position. It is a predictable outcome of funding a known-effective intervention at a dose too low to work.

The fix is specific: raise the cap to $300 per participant per month, or eliminate it and let clinical judgment determine appropriate incentive levels. The evidence has been there for decades. The decision to fund the shell of CM while starving it of the resources that make it work is not a technical miscalculation. It’s a policy choice. It has a body count.